文献速递浆细胞疾病造血干细胞移植与细胞治疗

靶向BCMA双特异性T细胞衔接器pavurutamab治疗复发/难治多发性骨髓瘤的1/1b期研究

A phase 1/1b study of the BCMA-targeting bispecific T-cell engager pavurutamab for relapsed/refractory multiple myeloma.
PubMed 文献 · Blood · 2026-01-01

该1/1b期开放标签剂量探索与扩展研究评估了pavurutamab单药治疗三重类药物复发/难治多发性骨髓瘤(RRMM)的安全性、耐受性和疗效。172例患者接受至少1剂pavurutamab,73例接受II期推荐剂量(RP2D;RP2D组总缓解率(ORR)为65.8%,≥非常好的部分缓解(VGPR)率为60.3%;中位缓解持续时间(DOR)为36.6个月。

要点

  • RP2D组未发生剂量限制性毒性,最常见不良事件为细胞因子释放综合征(CRS,74.4%)。
  • ≥3级感染发生率为34.9%,需关注感染风险。

核心结论

  • pavurutamab在重度经治RRMM患者中显示出可接受的安全性、药代动力学特征和初步疗效,支持anti-BCMA T细胞衔接器疗法。

研究设计与样本

  • 1/1b期、开放标签、剂量探索和剂量扩展研究,纳入三重类药物复发/难治多发性骨髓瘤(RRMM)患者。

主要发现

  • 最常见治疗中出现的不良事件包括CRS(74.4%)、贫血(61.0%)、中性粒细胞减少(47.1%)和低磷血症(45.3%)。
  • 60例患者(34.9%)发生≥3级感染。
  • 所有患者ORR为46.5%;RP2D组73例患者ORR为65.8%,≥VGPR率为60.3%。
  • 中位随访17.2个月时,中位DOR为36.6个月(95%CI 22.3至不可估计);所有患者中位PFS为5.5个月(95%CI 2.8-10.1),RP2D组为16.8个月(95%CI 5.0至不可估计)。

关键数值与推荐

  • RP2D组ORR 65.8%,≥VGPR率60.3%,中位DOR 36.6个月(95%CI 22.3至不可估计)。
  • 所有患者中位PFS 5.5个月(95%CI 2.8-10.1),RP2D组中位PFS 16.8个月(95%CI 5.0至不可估计)。

临床怎么用

  • 临床使用时需重点监测和管理CRS、感染及血液学毒性。
  • 高可溶性BCMA水平可能影响pavurutamab暴露,需关注其与疗效的关系。

局限性

  • 为1/1b期单臂研究,样本量有限,疗效需进一步随机对照研究验证。
  • 随访时间有限(中位17.2个月),长期疗效和安全性数据尚不充分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The B-cell maturation antigen (BCMA)-targeting bispecific T-cell engager pavurutamab (AMG 701) directs the cytotoxic T-cell response toward multiple myeloma (MM) cells. This phase 1/1b, open-label, dose-exploration and dose-expansion study evaluated the safety, tolerability, and efficacy of pavurutamab monotherapy in patients with triple-class relapsed/refractory MM (RRMM). Pavurutamab (5-18 000 μg) was administered IV weekly with step-up dosing in week 1. Overall, 172 patients received at least 1 dose of pavurutamab; 73 received the recommended phase 2 dose (RP2D; 18 000 μg), with 2 different step-up dosing regimens in phase 1b. Twelve patients had dose-limiting toxicities, which included cytokine release syndrome (CRS) and increased transaminases; none of which occurred at the RP2D. The most frequently reported treatment-emergent adverse events included CRS (74.4%), anemia (61.0%), neutropenia (47.1%), and hypophosphatemia (45.3%). Grade ≥3 infections were noted in 60 patients (34.9%). The overall response rate (ORR) was 46.5% among all patients and 65.8% (very good partial response [VGPR] or better, 60.3%) among 73 patients treated at the RP2D. At median follow-up of 17.2 months, median duration of response (DOR) was 36.6 months (95% confidence interval [CI], 22.3 to not estimable). Median progression-free survival (PFS) for all patients was 5.5 months (95% CI, 2.8-10.1) and 16.8 months (95% CI, 5.0 to not estimable) with the RP2D. Pavurutamab exposure generally increased in a dose-proportional manner, with high soluble BCMA levels correlating with lower exposure level. The acceptable safety profile, pharmacokinetics, and preliminary efficacy of pavurutamab supports anti-BCMA T-cell engager therapy in heavily pretreated patients with RRMM. This trial was registered at www.clinicaltrials.gov as NCT03287908.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Lee HC, Plattel WJ, Harrison SJ, et al. A phase 1/1b study of the BCMA-targeting bispecific T-cell engager pavurutamab for relapsed/refractory multiple myeloma. Blood. 2026. PMID: 41950113. doi:10.1182/blood.2025032044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。